
Please try another search
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. is headquartered in South San Francisco, California.
Name | Age | Since | Title |
---|---|---|---|
Craig C. Parker | 61 | 2018 | CEO, President & Director |
Calvin Kuo | - | - | Co-Founder & Member of Scientific Advisor |
K. Christopher Garcia | - | - | Co-Founder & Member of Scientific Advisory Board |
Roeland Nusse | 74 | - | Co-Founder & Member of Scientific Advisory Board |
Christopher Y. Chai | 57 | 2021 | Independent Director |
Mary Haak-Frendscho | 67 | 2021 | Independent Director |
Scott L. Friedman | - | 2022 | Member of Scientific Advisors |
Harold Eliot Varmus | - | - | Member of Scientific Advisors |
Bart Williams | - | - | Member of Scientific Advisors |
Willard H. Dere | 71 | - | Member of Scientific Advisors |
Mace L. Rothenberg | 67 | 2021 | Independent Director |
Timothy W. Kutzkey | 49 | 2025 | Independent Director |
Sarah Gillmor Hymowitz | - | 2022 | Member of Scientific Advisors |
Anna Berkenblit | 55 | 2018 | Independent Director |
Shao-Lee Lin | 57 | 2021 | Independent Director |
Eric H. Bjerkholt | 65 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review